Leads Biolabs moves PD-L1/4-1BB bispecific toward approval in rare aggressive neuroendocrine cancer
China’s Center for Drug Evaluation has accepted opamtistomig for previously treated advanced EP-NEC and placed the application under Priority Review, while detailed pivotal data await presentation.
